The unclear zone in phase II clinical trials

European Journal of Cancer

Volumn 46, Issue 13, 2010, Pages 2408-2413

  Allegro, Sabrina ^a   Pond, Gregory R ^a   Hotte, Sébastien J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Phase II clinical trials; Statistical inference

Indexed keywords

ALTERNATIVE HYPOTHESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; DATA EXTRACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; NEOPLASMS; SAMPLE SIZE;

EID: 77955917452     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.027     Document Type: Conference Paper

References (19)

1. A.J. Vickers, V. Ballen, and H.I. Scher Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing Clin Cancer Res 13 3 2007 972 976
2. T.R. Fleming One-sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
3. R. Simon Optimal two-stage design for phase II clinical trials Control Clin Trials 10 1989 1 10
4. M.J. Ratain, and T.G. Karrison Testing the wrong hypothesis in phase II oncology trials: there is a better alternative Clin Cancer Res 13 3 2007 781 782
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
6. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979.
7. T.G. Roberts Jr., T.J. Lynch Jr., and B.A. Chabner The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision J Clin Oncol 21 2003 3683 3695
8. S.N. Goodman P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate (plus commentary) Am J Epidemiol 137 5 1993 485 501
9. J.O. Berger Could Fisher, Jeffreys and Neyman have agreed on testing? (plus commentary) Stat Sci 18 1 2003 1 32
10. D.J. Blau, B.M. Jolles, and R. Porcher P value and the theory of hypothesis testing Clin Orthop Relat Res 468 2010 885 892
11. E.L. Lehmann The Fisher, Neyman-Pearson theories of testing hypotheses: one theory or two? J Am Stat Assoc 88 424 1993 1242 1249
12. J.I. Marden Hypothesis testing: from p values to Bayes factors J Am Stat Assoc 95 452 2000 1316 1320
13. M.N. Chang, and P.C. O'Brien Confidence intervals following group sequential tests Control Clin Trials 7 1 1986 18 26
14. L.C. Michaelis, and M. Ratain : Measuring response in a post-RECIST world: from black and white to shades of grey Nat Rev Cancer 6 2006 409 414
15. B. Booth, R. Glassman, and P. Ma Oncology's trials Nat Rev Drug Discov 2 2003 609 610
16. V.L. Rubinstein, E.L. Korn, and B. Freidlin Design issues of randomized phase II trials and a proposal for phase II screening trials J Clin Oncol 23 28 2005 7199 7206
17. S.M. Steinberg, and D.J. Venzon Early selection in a randomized phase II clinical trial Stat Med 21 2002 1711 1721
18. D.J. Sargent, V. Chan, and R.M. Goldberg A three-outcome design for phase II clinical trials Control Clin Trials 22 2 2001 117 125
19. P.F. Thall, and R. Simon A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials Control Clin Trials 15 6 1994 463 481